Post Profile






Sitagliptin + metformin in type 2 diabetes: Added benefit over sulfonylurea + metformin

(Institute for Quality and Efficiency in Health Care) An added benefit over other comparator therapies is not proven. The TECOS study also allowed no conclusions on the research questions of the Federal Joint Committee.
read more

share

Related Posts


Patients with type 2 diabetes taking JANUVIA® (sitagliptin), metformin initiated insulin therapy at a slower rate compared to patients taking a sulfonylurea, metformin

Academics / General Science : ScienceDaily: Science Society

A late-breaking observational study has been released that assessed the differences in time to initiation of insulin use and the proportion of the population initiating insulin among patients with type 2 diabetes taking the combinat...

Selexipag in pulmonary arterial hypertension: Added benefit not proven

Health : EurekAlert: Health

(Institute for Quality and Efficiency in Health Care) The data in the dossier were unsuitable to show an added benefit: Comparator therapy and division of the population were inadequate.

Study Shows Januvia(TM) (sitagliptin) Offered Significant Blood Sugar-Lowering Efficacy In Combination With Insulin In Type 2 Diabetes

Health : Medical News Today

A new investigational study presented at the American Diabetes Association (ADA) 69th Annual Scientific Sessions showed that 'Januvia' (sitagliptin), when added to ongoing insulin therapy with or without metformin, significantly imp...

Mortality increased by 58% when sulfonylureas used as first-line therapy for type 2 diabetes instead of metformin

Health : Medical News Today

New research presented at this year's annual meeting of the European Association for the Study of Diabetes (EASD) in Barcelona, Spain, shows that patients receiving sulfonylureas as first line treatment for type 2 diabetes have high...

Saxagliptin and saxagliptin/metformin in type 2 diabetes: Added benefit not proven

Health : EurekAlert: Health

(Institute for Quality and Efficiency in Health Care) The presented analyses of the SAVOR-TIMI 53 study were unsuitable for conclusions on positive or negative effects in comparison with the appropriate comparator therapies.

Comments


Copyright © 2016 Regator, LLC